IGM Biosciences (IGMS) Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IGMS shares.
View IGMS analyst ratings or view top-rated stocks.

8 brokerages have issued 1-year price objectives for IGM Biosciences' shares. Their IGMS share price forecasts range from $11.00 to $55.00. On average, they anticipate the company's stock price to reach $23.60 in the next twelve months. This suggests a possible upside of 224.2% from the stock's current price.
View analysts price targets for IGMS or view top-rated stocks among Wall Street analysts.

IGM Biosciences' stock was trading at $17.01 at the beginning of the year. Since then, IGMS stock has decreased by 57.2% and is now trading at $7.28.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IGMS earnings forecast.

IGM Biosciences, Inc. (NASDAQ:IGMS) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($1.40) by $0.03. The business earned $0.45 million during the quarter, compared to analysts' expectations of $0.80 million. IGM Biosciences had a negative trailing twelve-month return on equity of 84.18% and a negative net margin of 14,007.47%. The company's revenue for the quarter was up 22.4% on a year-over-year basis. During the same period in the previous year, the business earned ($1.33) EPS.

ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

(IGMS) raised $125 million in an IPO on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

IGM Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Artal Group S.A. (5.85%), RA Capital Management L.P. (1.61%), BlackRock Inc. (1.99%), Goldman Sachs Group Inc. (1.15%), Great Point Partners LLC (0.86%) and State Street Corp (0.45%). Insiders that own company stock include Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg and Misbah Tahir.
View institutional ownership trends.

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IGMS stock can currently be purchased for approximately $7.28.

IGM Biosciences (NASDAQ:IGMS) has a market capitalization of $424.93 million and generates $1.07 million in revenue each year. The company earns $-221,100,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis.

The company employs 289 workers across the globe.

IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is igmbio.com. The company can be reached via phone at 650-965-7873.